

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 7, 2001

IMMUNOGEN, INC.
(Exact name of registrant as specified in its Charter)

Massachusetts (State or other jurisdiction of incorporation)	0-17999 (Commission File Number)	04-2726691 (IRS Employer Identification No.)
--	--	--

128 Sidney Street, Cambridge, Massachusetts (Address of principal executive offices)	02139 (Zip Code)
---	---------------------

Registrant's telephone number, including area code: (617) 995-2500

ITEM 5. OTHER EVENTS

On March 5, 2001, ImmunoGen, Inc. ("ImmunoGen") announced that it had entered into a collaboration agreement with Millennium Pharmaceuticals, Inc. ImmunoGen will receive an upfront payment of \$2.0 million. In addition to royalties on net sales, the terms of the agreement include milestone payments, assuming all benchmarks are met, for potentially more than \$41.0 million per target.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

None.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

ImmunoGen, Inc.
(Registrant)

Date: March 7, 2001

/s/ MITCHEL S. SAYARE

Mitchel S. Sayare
Chairman and CEO